{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=96", "query": { "intervention": "Cohorting", "page": 96 }, "page_size": 10 }, "pagination": { "page": 96, "page_size": 10, "total_count": 11389, "total_pages": 1139, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=97&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=95&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T23:30:01.311Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06998342", "title": "MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma (CSCC)" ], "interventions": [ { "name": "Short course radiation", "type": "RADIATION" }, { "name": "Active Surveillance", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "University of Vermont Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-06-04", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998342" }, { "nct_id": "NCT07084883", "title": "Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Age-related Macular Degeneration (AMD)" ], "interventions": [ { "name": "No intervention.", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "iHealthScreen Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1076, "start_date": "2024-08-01", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "Richmond Hill, New York", "locations": [ { "city": "Richmond Hill", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07084883" }, { "nct_id": "NCT01303705", "title": "Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer", "Cancer of the Prostate", "Prostate Cancer" ], "interventions": [ { "name": "Anti-OX40", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2010-10-14", "completion_date": "2016-07-05", "has_results": false, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01303705" }, { "nct_id": "NCT04270682", "title": "Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CTX" ], "interventions": [ { "name": "Blinded CDCA 250 mg TID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Open-Label CDCA 250 mg TID", "type": "DRUG" }, { "name": "Rescue Medication CDCA 250 mg TID", "type": "DRUG" }, { "name": "CDCA Weight-Based Dose TID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": null, "sex": "ALL", "summary": "1 Month and older" }, "enrollment_count": 19, "start_date": "2020-01-31", "completion_date": "2023-10-04", "has_results": true, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 9, "location_summary": "Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04270682" }, { "nct_id": "NCT04476524", "title": "Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient Management From the ER", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiac Arrhythmia", "Atrial Fibrillation" ], "interventions": [ { "name": "Quality improvement", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Kansas City Heart Rhythm Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-08-15", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-02-04", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04476524" }, { "nct_id": "NCT01837862", "title": "A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pilomyxoid Astrocytoma", "Pilocytic Astrocytoma", "Glioma, Astrocytic", "Optic Nerve Glioma", "Pleomorphic Xanthoastrocytoma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Gliosarcoma", "Diffuse Intrinsic Pontine Glioma", "DIPG", "Low-grade Glioma", "Brainstem Glioma" ], "interventions": [ { "name": "Mebendazole", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie Krystal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 10, "start_date": "2013-10-22", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837862" }, { "nct_id": "NCT03114462", "title": "Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasms of Respiratory and Intrathoracic Organs", "Squamous Cell Carcinoma of the Larynx" ], "interventions": [ { "name": "Stereotactic Hypofractionated Radioablation", "type": "RADIATION" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "RADIATION", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-08-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03114462" }, { "nct_id": "NCT03357627", "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Large B-cell, Diffuse", "Lymphoma, Follicular" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-02-16", "completion_date": "2021-08-03", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Evanston, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Shelbyville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03357627" }, { "nct_id": "NCT04046224", "title": "Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "ST-920", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sangamo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-07-23", "completion_date": "2025-04-10", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 9, "location_summary": "Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046224" }, { "nct_id": "NCT01789827", "title": "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-03", "completion_date": "2018-06-27", "has_results": false, "last_update_posted_date": "2019-08-05", "last_synced_at": "2026-11-02T23:30:01.311Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01789827" } ] }